Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Avugane
- Development stage
- Phase 2
- Lead developer
- Valerio Therapeutics
- Modality
- Small Molecules
- Administration
- Topical
01
Overview
Avugane is a topical formulation of valproic acid, a small molecule histone deacetylase (HDAC) inhibitor, developed by TopoTarget A/S for the treatment of mild to moderate acne vulgaris. By inhibiting HDACs, Avugane modulates the expression of genes involved in inflammatory responses and keratinocyte proliferation, which are key factors in the pathogenesis of acne. The drug reached Phase II clinical development, where it was tested in randomized, placebo-controlled trials to evaluate its efficacy and safety at various concentrations. However, development appears to have been discontinued as it no longer appears in active pipelines.
- Brand names
- Avugane
02
Targets
HDAC (HDAC family)
Beyond the preview
Go deeper on Avugane.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Avugane.